Market Indices
Latest News
 |
| ||
| ||
| ||
|
Price Targets
Mark Hughes from Truist Financial issued a price target of $39.00 for HRTG on 2026-03-09 19:58:00.The adjusted price target was set to $39.00.At the time of the announcement,
March 9, 2026 HRTG 0.78%
Maury Raycroft from Jefferies issued a price target of $98.00 for DNTH on 2026-03-09 19:51:00.The adjusted price target was set to $98.00.At the time of the announcement, DNTH...
March 9, 2026 DNTH 20.94%
Trevor Allred from Oppenheimer issued a price target of $145.00 for DNTH on 2026-03-09 14:15:00.The adjusted price target was set to $145.00.At the time of the announcement, DNTH...
March 9, 2026 DNTH 20.94%
Alex Thompson from Stifel Nicolaus issued a price target of $120.00 for DNTH on 2026-03-09 14:14:00.The adjusted price target was set to $120.00.At the time of the announcement,
March 9, 2026 DNTH 20.94%
Michael Shlisky from D.A. Davidson issued a price target of $23.00 for MEC on 2026-03-09 12:41:00.The adjusted price target was set to $23.00.At the time of the announcement,
March 9, 2026 MEC -1.36%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| EGRX Eagle Pharmaceuticals, In | 0.34
127.40% | ||||||||||||||||||
| ATRA Atara Biotherapeutics, In | 6.76
30.75% | ||||||||||||||||||
| DNTH Dianthus Therapeutics, In | 78.85
20.94% | ||||||||||||||||||
| TMCWW TMC the metals company In | 0.86
20.49% | ||||||||||||||||||
| AXTI AXT, Inc. | 38.50
18.92% | ||||||||||||||||||
| BTAI BioXcel Therapeutics, Inc | 1.76
18.92% | ||||||||||||||||||
| CCCC C4 Therapeutics, Inc. | 3.57
17.27% | ||||||||||||||||||
| SLDB Solid Biosciences Inc. | 7.92
17.26% | ||||||||||||||||||
Annual/Quarterly Reports Summary
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
November 6, 2024 AIP -0.45%
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
November 6, 2024 EOSEW -34.96%
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
November 6, 2024 EOSE -0.16%
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
November 5, 2024 STOK 7.81%
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
November 5, 2024 BSVN -3.48%